Literature DB >> 9149110

Up-regulation of D3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities.

D M Segal1, C T Moraes, D C Mash.   

Abstract

The effects of chronic cocaine use on D3 receptor mRNA expression in the human nucleus accumbens was assessed by reverse transcription-polymerase chain reaction. D3 receptor/cyclophilin mRNA ratios in the nucleus accumbens were increased 6-fold in cocaine overdose victims as compared to age-matched and drug-free control subjects. This finding demonstrates that chronic cocaine exposure leads to adaptive increases in the expression of D3 receptor mRNA in a critical reward center in brain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9149110     DOI: 10.1016/s0169-328x(97)00025-9

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  49 in total

1.  The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access.

Authors:  Laura Orio; Sunmee Wee; Amy H Newman; Luigi Pulvirenti; George F Koob
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

Review 2.  Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Authors:  K Fuxe; D Marcellino; D O Borroto-Escuela; M Guescini; V Fernández-Dueñas; S Tanganelli; A Rivera; F Ciruela; L F Agnati
Journal:  CNS Neurosci Ther       Date:  2010-03-16       Impact factor: 5.243

3.  Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study.

Authors:  Isabelle Boileau; Doris Payer; Sylvain Houle; Arian Behzadi; Pablo M Rusjan; Junchao Tong; Diana Wilkins; Peter Selby; Tony P George; Martin Zack; Yoshiaki Furukawa; Tina McCluskey; Alan A Wilson; Stephen J Kish
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

4.  Molecular characterization of individual D3 dopamine receptor-expressing cells isolated from multiple brain regions of a novel mouse model.

Authors:  Ying Li; Eldo V Kuzhikandathil
Journal:  Brain Struct Funct       Date:  2012-01-29       Impact factor: 3.270

Review 5.  The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Authors:  Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; Jim J Hagan; Charles R Ashby
Journal:  Brain Res Brain Res Rev       Date:  2005-07

6.  Reduction of cocaine self-administration and D3 receptor-mediated behavior by two novel dopamine D3 receptor-selective partial agonists, OS-3-106 and WW-III-55.

Authors:  Timothy H C Cheung; Amy L Loriaux; Suzanne M Weber; Kayla N Chandler; Jeffrey D Lenz; Romina F Schaan; Robert H Mach; Robert R Luedtke; Janet L Neisewander
Journal:  J Pharmacol Exp Ther       Date:  2013-09-09       Impact factor: 4.030

7.  Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [11C]-+-PHNO.

Authors:  Doris E Payer; Arian Behzadi; Stephen J Kish; Sylvain Houle; Alan A Wilson; Pablo M Rusjan; Junchao Tong; Peter Selby; Tony P George; Tina McCluskey; Isabelle Boileau
Journal:  Neuropsychopharmacology       Date:  2013-08-07       Impact factor: 7.853

Review 8.  Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.

Authors:  Christian Heidbreder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-10-28       Impact factor: 3.000

9.  The dopamine D3 receptor partial agonist CJB 090 inhibits the discriminative stimulus but not the reinforcing or priming effects of cocaine in squirrel monkeys.

Authors:  Cindy Achat-Mendes; Donna M Platt; Amy H Newman; Roger D Spealman
Journal:  Psychopharmacology (Berl)       Date:  2009-06-10       Impact factor: 4.530

Review 10.  Neuropathology of substance use disorders.

Authors:  Jean Lud Cadet; Veronica Bisagno; Christopher Mark Milroy
Journal:  Acta Neuropathol       Date:  2013-11-29       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.